NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Do you know this is their plan, or is it your opinion?

Clearly, when they are patient matching, they should not select idh1 mutant patients in the ECA arm against idh1 wildtype in the treatment arm. That’s just foolhardy.

They can get matches from trials and/or hospital registries.

They could also use it for comparing placebo versus treatment arm.

What you are saying only makes sense if the PR department has told you what you are saying is correct.